Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Soft Tissue Injuries D017695 2 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Bronchial Diseases D001982 3 associated lipids
Pneumonia, Pneumococcal D011018 3 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Ileal Diseases D007077 3 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Enterocolitis, Necrotizing D020345 3 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Page CP et al. An in vivo model for studying platelet aggregation and disaggregation. 1982 Thromb. Haemost. pmid:7051409
Camussi G et al. Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness: role of basophil-derived PAF in immune complex deposition. 1982 J. Immunol. pmid:7054286
Ninio E et al. Biosynthesis of platelet-activating factor. I. Evidence for an acetyl-transferase activity in murine macrophages. 1982 Biochim. Biophys. Acta pmid:7055592
Long MW et al. Immature megakaryocytes in the mouse: physical characteristics, cell cycle status, and in vitro responsiveness to thrombopoietic stimulatory factor. 1982 Blood pmid:7059669
Humphrey DM et al. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. 1982 Lab. Invest. pmid:7070056
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Morgat JL et al. Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. 1982 Agents Actions pmid:7164942
Convert O et al. 1H NMR of PAF-acether: influence of solvent on its structure. 1982 Agents Actions pmid:7164943
Borrel MC et al. Additional techniques for the total synthesis of PAF-acether. 1982 Agents Actions pmid:7164944
Benveniste J et al. Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. 1982 Agents Actions pmid:7164945
Arnoux B et al. Release of PAF-acether from human blood monocytes. 1982 Agents Actions pmid:7164946
Fouque F et al. Platelet-activating factor (PAF-acether): thromboxane-independent synergism with adrenaline on human platelets and recent insights into its mode of action. 1982 Agents Actions pmid:7164947
Lefort J et al. Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. 1982 Agents Actions pmid:7164948
Lanara E et al. Response of mice and mouse platelets to acetyl glyceryl ether phosphorylcholine. 1982 Biochem. Biophys. Res. Commun. pmid:7168759
Isobe J and Mizuno A Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. 1982 Tokushima J. Exp. Med. pmid:7170716
Czarneztki BM Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release. 1982 Chem. Phys. Lipids pmid:6814773
Basran GS et al. Cromoglycate (DSCG) inhibits responses to platelet-activating factor (PAF-acether) in man: an alternative mode of action for DSCG in asthma? 1982 Eur. J. Pharmacol. pmid:6819153
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Roussi J et al. [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. 1983 Nouv Rev Fr Hematol pmid:6622253
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519